SCHEMBL643115

SCHEMBL643115

O=C(O)CC1CCCN1S(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.60
HTR1A P08908 1/20 0.60
DRD2 P14416 1/20 0.60
HTR1D P28221 1/20 0.60
HTR1B P28222 1/20 0.60
HTR1E P28566 1/20 0.60
ADRA1B P35368 1/20 0.60
DRD3 P35462 1/20 0.60
TSHR P16473 2/20 0.60
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
HCRTR1 O43613 3/20 0.54
HCRTR2 O43614 3/20 0.54
RECQL P46063 1/20 0.54
LMNA P02545 1/20 0.50
PSEN1 P49768 2/20 0.47
PSEN2 P49810 2/20 0.47
APH1B Q8WW43 2/20 0.47
NCSTN Q92542 2/20 0.47
APH1A Q96BI3 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL645236 0.96 TSHR (0.59) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL644395 0.86 HTR7 (0.59) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL5092685 0.85 HTR7 (0.55) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL14829372 0.84 HTR7 (0.57) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL14829143 0.83 HTR7 (0.64) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL643313 0.82 HTR7 (0.55) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL3638393 0.82 HTR7 (0.58) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL2707126 0.82 TSHR (0.73) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL2707134 0.82 TSHR (0.73) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL5088383 0.82 TSHR (0.54) HTR7HTR1ADRD2HTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A HTR7 1720/4885HTR1A 799/4885DRD2 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.